» Articles » PMID: 8038898

Protein Levels and Plasmapheresis Intensity

Overview
Journal Transfus Med
Specialty Hematology
Date 1993 Mar 1
PMID 8038898
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In order to evaluate the influence of intensity of plasmapheresis on donor serum total protein and immunoglobulin concentrations, these parameters were measured monthly in two groups of plasma donors over a period of 6 months. Donors in group one donated 500-600 ml of plasma at weekly intervals and those in the other groups at intervals of 14 days or longer. Regular whole blood donors were used as a control group. The average concentrations of total protein and IgG immunoglobulin fraction in group one were significantly lower (P < 0.002) than those of the other two groups but they always remained well within the normal ranges. Although the mean total protein level of this group of donors fell significantly during the first 3 months, their values returned to almost baseline levels at the end of the study. No statistically significant difference from the initial concentrations was observed during monthly measurements of IgG, IgA and IgM levels among any of the groups studied. We conclude that removal of 500-600 ml of plasma at weekly intervals involves little, if any, risk of total protein or immunoglobulin depletion in donors who satisfy current criteria. This study also suggests that the frequency of IgG and IgM evaluations may be safely lowered and that IgA determinations may be limited to first time plasma donors.

Citing Articles

The effect of donation frequency on donor health in blood donors donating plasma by plasmapheresis: study protocol for a randomized controlled trial.

Haugen M, Magnussen K, Aarsland T, Nissen-Meyer L, Strand T Trials. 2024; 25(1):175.

PMID: 38468338 PMC: 10926559. DOI: 10.1186/s13063-024-08035-7.


Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.

Nurarifah N, Brahmantyo H, Wardhani S, Hermanto D, Arsana P Front Immunol. 2021; 12:633323.

PMID: 34790190 PMC: 8591125. DOI: 10.3389/fimmu.2021.633323.


Repeat donation and deferral rates in US source plasma donors: Exploratory analysis from the IMPACT trial.

Hartmann J, Ragusa M, Burchardt E, Manukyan Z, Popovsky M, Leitman S Transfusion. 2021; 61(10):2849-2854.

PMID: 34309028 PMC: 9290731. DOI: 10.1111/trf.16610.


Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.

Annen K, Morrison T, DomBourian M, McCarthy M, Huey L, Merkel P Transfusion. 2021; 61(4):1148-1159.

PMID: 33452828 PMC: 8014809. DOI: 10.1111/trf.16261.


Source plasma collection in the United States: Toward a more personalized approach.

Hartmann J, Ragusa M, Popovsky M, Leitman S Am J Hematol. 2020; 95(6):E139-E142.

PMID: 32243619 PMC: 7318202. DOI: 10.1002/ajh.25817.